Small change for big improvement in the preparation of the key intermediate N1, N3-disubstituted 1,3,5-triazone of ensitrelvir-Reference-Cited by-同舟云学术

Small change for big improvement in the preparation of the key intermediate N¹, N³-disubstituted 1,3,5-triazone of ensitrelvir

Published:2023 Issue:6 Volume:13 Page:3688-3693
ISSN:2046-2069
Container-title:RSC Advances
language:en
Short-container-title:RSC Adv.

Author:

Hu Wei¹,Liu Yuanchang¹,Zhang Xiang¹,Zheng Panpan¹^ORCID,Yang Feifei¹,Guo Guangyang¹,Xie Xin¹²,Huang Jiuzhong¹²^ORCID,Chen Weiming¹²^ORCID

Affiliation:

1. School of Pharmaceutical Sciences, Gannan Medical University, Ganzhou 341000, P. R. China

2. Key Laboratory of Prevention and Treatment of Cardiovascular and Cerebrovascular Diseases of Ministry of Education, Gannan Medical University, Ganzhou 341000, P. R. China

Abstract

A four-step telescoped strategy for synthesis of the key intermediate of ensitrelvir, approved in Japan for the treatment of SARS-CoV-2 infection under the emergency regulatory approval system, was developed.

Funder

5511 Science and Technology Innovation Talent Project of Jiangxi Province

Natural Science Foundation of Jiangxi Province

Publisher

Royal Society of Chemistry (RSC)

Subject

General Chemical Engineering,General Chemistry

Link

http://pubs.rsc.org/en/content/articlepdf/2023/RA/D2RA07844A

Reference14 articles.

1. An oral SARS-CoV-2 M pro inhibitor clinical candidate for the treatment of COVID-19

2. Discovery of SARS-CoV-2 antiviral drugs through large-scale compound repurposing

3. Characteristics of SARS-CoV-2 and COVID-19

4. COVID-19, Influenza and RSV: Surveillance-informed prevention and treatment – Meeting report from an isirv-WHO virtual conference

5. WHO Solidarity Trial Consortium , Repurposed antiviral drugs for COVID-19 - interim WHO solidarity trial results . N. Engl. J. Med. 2021 , 384 , 497511